Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

Thematic Report on India’s Auto Boom: Is Policy the New Fuel Igniting a Cyclical Revival?

OneSource Specialty Pharma: Building a Global CDMO Champion from India

The Beat Ideas: Amanta Healthcare IPO - Navigating Growth in the Sterile Pharma Space.

Thematic Report on H-1B Visa Impact: Can Brain Drain in US Become Brain Gain for India?

The Beat Ideas: Styrenix Performance Ltd - Unlocking Synergies with Acquisition of INEOS Thailand

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Event-Driven

Onesource Specialty Pharma / Event-Driven

<ul>
<li>OneSource Specialty Pharma has approved a Composite Scheme of Arrangement to acquire Steriscience's EuropeanCDMO and Brooks Steriscience’s Indian anti-infective assets. 
</li>
<li>The transaction adds approximately $107 million in projected FY27 revenue, significantly diversifying the portfolio, reducing single-site risk, raising the consolidated FY28 revenue outlook to over $500 million.</li>
<li>While the acquisition multiples appear steep for subscale assets, if management successfully delivers on ambitious growth targets, the transaction could position OneSource among the most competitive players in CDMO landspace.</li>
</ul>


OneSource Specialty Pharma has approved a Composite Scheme of Arrangement to acquire Steriscience's EuropeanCDMO and Brooks Steriscience’s Indian anti-infective assets. 

The transaction adds approximately $107 million in projected FY27 revenue, significantly diversifying the portfolio, reducing single-site risk, raising the consolidated FY28 revenue outlook to over $500 million.
While the acquisition multiples appear steep for subscale assets, if management successfully delivers on ambitious growth targets, the transaction could position OneSource among the most competitive players in CDMO landspace.


Decoding OneSource Pharma’s Strategic Amalgamation: A Blueprint for a Global CDMO Powerhouse?